KEY POINTS
- This retrospective single-center study evaluated 60 patients with localized prostate cancer treated with definitive SBRT between June 2023 and February 2026. The primary endpoint was acute CTCAE grade ≥2 genitourinary toxicity within 90 days of radiotherapy. Median age was 72 years, median baseline IPSS was 7, and 17 patients (28.3%) had periurethral calcifications visible on pretreatment planning CT.
- Patients received either 40 Gy in five fractions or 42.7 Gy in seven fractions, delivered twice weekly using CBCT-guided online adaptive radiotherapy on a Varian Ethos system. Elective pelvic nodal irradiation was included when indicated, delivering 25 Gy in five fractions or 28 Gy in seven fractions. Prostate/seminal vesicle PTV margins were 3 mm except 2 mm posteriorly, and baseline bladder and urethral dose metrics were comparable between patients with and without calcifications.
- Periurethral calcifications were defined as at least two discrete hyperdense foci adjacent to the prostatic urethra, or one focus visible on at least three consecutive axial CT slices. Assessment was performed independently by blinded observers using a predefined window setting, with 93.3% agreement (56/60 patients) and Cohen's κ of 0.84 (95% CI 0.68–0.99), demonstrating high reproducibility within the study cohort.
- Overall, 21/60 patients (35%) developed acute grade ≥2 GU toxicity. The event rate was substantially higher among patients with calcifications: 11/17 (64.7%) versus 10/43 (23.3%), an absolute difference of 41.4 percentage points. The unadjusted odds ratio was 6.05 (95% CI 1.78–20.51; p=0.006), indicating a strong association between this imaging finding and clinically meaningful acute urinary symptoms.
- After adjustment for baseline IPSS using Firth penalized logistic regression, periurethral calcifications remained associated with acute grade ≥2 GU toxicity (adjusted OR 6.90, 95% CI 1.97–27.96; p=0.002). Higher pretreatment IPSS also independently contributed to the model (OR 1.13 per IPSS point, 95% CI 1.03–1.27; p=0.008), suggesting that the calcification finding may provide information beyond baseline symptom severity.
- Importantly, urethral Dmax was almost identical in patients with and without calcifications (41.16 vs 41.17 Gy; p=0.983), while bladder V18.1 Gy and V37 Gy did not differ significantly. Acute grade ≥3 GU toxicity occurred in three patients (5%), including two with periurethral calcifications; two patients required temporary catheterization for urinary retention. The small number of severe events prevented a reliable analysis of whether calcifications also predict grade ≥3 toxicity.
- The authors propose that periurethral calcifications may reflect pre-existing inflammation, fibrosis, or reduced periurethral tissue compliance, potentially increasing vulnerability to radiation-induced edema. However, these mechanisms were not directly tested. The study had only 21 primary endpoint events, limited multivariable adjustment, clinician-reported rather than patient-reported toxicity, and no mature late-toxicity analysis; the imaging definition was also developed specifically for this investigation.
CLINICAL TAKEAWAY
Periurethral calcifications on routine prostate planning CT may offer a simple, inexpensive imaging marker for identifying patients at increased risk of acute urinary toxicity after SBRT, even when conventional urethral and bladder dose metrics are similar. However, the association comes from a small retrospective cohort and should not yet guide treatment exclusion, prescription modification, or additional dose constraints without prospective external validation.